NCT01163227View on ClinicalTrials.gov

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Schizophrenia Disorders
Interventions
DRUG

Placebo (single and multiple doses)

DRUG

AQW051 2 mg (single and multiple doses)

DRUG

AQW051 15mg (single and multiple doses)

DRUG

AQW051 100mg (single dose), and 50mg (multiple doses)

Trial Locations (2)

91206

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,, Glendale

08046

CRI Worldwide, 1113 Hospital Dr. Suite 202,, Willingboro

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY